Lenvatinib (LEN) plus pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.

被引：0
|
作者：
Lee, Chung-Han
Shah, Amishi Yogesh
Hsieh, James J.
Rao, Arpit
Pinto, Alvaro
Bilen, Mehmet Asim
Cohn, Allen Lee
DiSimone, Christopher
Shaffer, David R.
Sarrio, Regina Girones
Ribe, Sara Gunnestad
Wu, Jane
Schmidt, Emmett V.
Kubiak, Peter
Okpara, Chinyere
Smith, Alan D.
Motzer, Robert J.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[3] Washington Univ, Sch Med, Dept Med, Oncol Div, St Louis, MO 63110 USA
[4] South Texas Accelerated Res Therapeut, Dept Clin Res, San Antonio, TX USA
[5] Hosp Univ La Paz, Serv Oncol, Madrid, Spain
[6] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[7] US Oncol Res, Rocky Mt Canc Ctr, Med Oncol, Denver, CO USA
[8] Arizona Oncol Associates, Med Oncol Hematol, Tucson, AZ USA
[9] New York Oncol Hematol, US Oncol Res, Med Oncol, Albany, NY USA
[10] Hosp Univ & Politecn FE, Med Oncol Serv, Valencia, Spain
[11] Sorlandet Hosp Kristiansand, Med Oncol, Kristiansand, Norway
[12] Eisai Inc, Biostat, Woodcliff Lake, NJ USA
[13] Merck & Co Inc, Clin Res, Kenilworth, NJ USA
[14] Eisai Inc, Clin Res, Woodcliff Lake, NJ USA
[15] Eisai Ltd, Clin Res, Hatfield, Herts, England
[16] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16542
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16542
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [32] Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Porta, Camillo
    Alekseev, Boris
    Rha, Sun Young
    Choueiri, Toni K.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Goh, Jeffrey C.
    Eto, Masatoshi
    Wang, Jinyi
    Pan, Janice
    Asfaw, Alemseged Ayele
    He, Cixin Steven
    Mody, Kalgi
    Cella, David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN plus PEM).
    Haro-Silerio, Jaime Ivan
    Johns, Andrew
    Moussa, Mohammad Jad
    Wang, Mindy
    Wang, Emily
    Kovitz, Craig A.
    Campbell, Matthew T.
    Jonasch, Eric
    Shah, Amishi Yogesh
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 433 - 433
  • [34] Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Preliminary results of cohort 1 of the phase 1 LITESPARK-010 study
    Sheng, Xinan
    Guo, Hongqian
    Yao, Xin
    Zhou, Fangjian
    Chen, Jimin
    Zhang, Shun
    Li, Juan
    Diao, Lei
    Dong, Pei
    Li, Xiaoqing
    Zhang, Zhewei
    Chain, Anne
    Zhu, Pengfei
    Zhang, Weijuan
    Wang, Ding
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results.
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew W.
    Taylor, Matthew H.
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Schmidt, Emmett V.
    Guo, Matthew
    Dutcus, Corina E.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) plus lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
    Albiges, L.
    Gurney, H. P.
    Atduev, V.
    Suarez, C.
    Climent Duran, M. A.
    Pook, D.
    Tomczak, P.
    Barthelemy, P.
    Lee, J-L.
    Nalbandian, T.
    Stus, V.
    Ferguson, T.
    Wiechno, P.
    Gokmen, E.
    Lacombe, L.
    Gedye, C.
    Perini, R.
    Sharma, M.
    Li, C.
    Lee, C-H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1204 - S1204
  • [37] Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
    Lee, Chung-Han
    Shah, Amishi Yogesh
    Rasco, Drew
    Rao, Arpit
    Taylor, H. Matthew
    Di Simone, Christopher
    Hsieh, J. James
    Pinto, Alvaro
    Shaffer, R. David
    Sarrio, Regina Girones
    Cohn, Allen Lee
    Vogelzang, J. Nicholas
    Bilen, Mehmet Asim
    Ribe, Sara Gunnestad
    Goksel, Musaberk
    Tennoe, Oyvind Krohn
    Richards, Donald
    Sweis, F. Randy
    Courtright, Jay
    Heinrich, Daniel
    Jain, Sharad
    Wu, Jane
    Schmidt, V. Emmett
    Perini, F. Rodolfo
    Kubiak, Peter
    Okpara, E. Chinyere
    Smith, D. Alan
    Motzer, J. Robert
    LANCET ONCOLOGY, 2021, 22 (07): : 946 - 958
  • [38] Final database lock results of the phase 2 cohort of lenvatinib plus pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma
    Lee, Chung-Han
    Shah, Amishi Yogesh
    Rao, Arpit
    Taylor, Matthew H.
    Pinto, Alvaro
    Sarrio, Regina Girones
    Cohn, Allen Lee
    Bilen, Mehmet Asim
    Ribe, Sara Gunnestad
    Goksel, Musaberk
    Tennoe, Oyvind Krohn
    Richards, Donald
    Sweis, Randy F.
    Heinrich, Daniel
    Perini, Rodolfo
    Kubiak, Peter
    Huang, Jie
    Motzer, Robert J.
    ONCOLOGIST, 2023, 28 : S3 - +
  • [39] Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial.
    Lee, Chung-Han
    Fitzgerald, Kelly N.
    Voss, Martin H.
    Carlo, Maria Isabel
    Knezevic, Andrea
    Peralta, Laura
    Chen, Ying-Bei
    Zucker, Mark
    Lefkowitz, Robert A.
    Reznik, Eduard
    Shah, Neil J.
    Owens, Colette Ngozi
    McHugh, Deaglan Joseph
    Aggen, David H.
    Laccetti, Andrew Leonard
    Kotecha, Ritesh R.
    Feldman, Darren R.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC)
    Motzer, Robert J.
    Grunwald, Viktor
    Hutson, Thomas E.
    Porta, Camillo
    Fowles, Thomas
    Eto, Masatoshi
    Dutcus, Corina E.
    Baig, Mahadi Ali
    Dutta, Lea
    Li, Di
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345